LXRX (Lexicon Pharmaceuticals) Notes Receivable: $0.00 Mil (As of Mar. 2026)


LXRX Lexicon Pharmaceuticals Inc LXRX
57 GF Score
Price $2.32
GF Value $8.36
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Lexicon Pharmaceuticals Notes Receivable?

Lexicon Pharmaceuticals LXRX -0.85% 57 Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus rates LXRX with a GF Score™ of 57/100 and a GF Value™ of $8.36 (Possible Value Trap). The stock has 5 warning signs investors should review.

Lexicon Pharmaceuticals's Notes Receivable for the quarter that ended in Mar. 2026 was $0.00 Mil.

Lexicon Pharmaceuticals Notes Receivable Related Terms

Lexicon Pharmaceuticals Notes Receivable Historical Data

* Premium members only.

The historical data trend for Lexicon Pharmaceuticals's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lexicon Pharmaceuticals Notes Receivable Chart

Lexicon Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Lexicon Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LXRX
57GF Score
Lexicon Pharmaceuticals Inc LXRX
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lexicon Pharmaceuticals Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of $0.00 Mil mean?
Lexicon Pharmaceuticals (LXRX) has a Notes Receivable of $0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lexicon Pharmaceuticals and its competitors.
Is Lexicon Pharmaceuticals' Notes Receivable too high?
Lexicon Pharmaceuticals' current Notes Receivable is $0.00 Mil. Overall, Lexicon Pharmaceuticals has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lexicon Pharmaceuticals' Notes Receivable compare to CGEM and WVE?
Lexicon Pharmaceuticals' Notes Receivable of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Lexicon Pharmaceuticals and its competitors. Lexicon Pharmaceuticals's current Notes Receivable is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexicon Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lexicon Pharmaceuticals (LXRX) is currently considered Possible Value Trap. The stock's GF Value™ is $8.36, compared to a current price of $2.32 — trading 72.2% below its estimated fair value. The current Notes Receivable is $0.00 Mil. Lexicon Pharmaceuticals' overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Lexicon Pharmaceuticals (LXRX), the current Notes Receivable is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lexicon Pharmaceuticals (LXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Lexicon Pharmaceuticals stock appears to be undervalued. The current stock price of $2.32 is trading 72.2% below its estimated GF Value™ of $8.36. GuruFocus considers Lexicon Pharmaceuticals to be Possible Value Trap.

Key valuation signals for LXRX:

  • Notes Receivable: $0.00 Mil
  • GF Value™: $8.36 vs. price of $2.32 (72.2% below fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the LXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lexicon Pharmaceuticals Business Description

Address 2445 Technology Forest Boulevard, 11th Floor, The Woodlands, TX, USA, 77381
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
57GF Score

Get the complete analysis for LXRX

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.32
Price
$8.36
GF Value